Lung Cancer Trials Ask AI to find trials
TerminatedPhase 4NCT03006562
Official study title

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Study summary

The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).

Ask AI to explain this study
Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedSubcutaneous Heparin

The study team can explain what participation involves.

Who it may be forProstate Cancer · Venous Thromboembolism

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 5, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Johns Hopkins University

Study sponsor

01
Study overview

What this study is about

Purpose
Prevention
Study type
Interventional
Phase
Phase 4
Sponsor
Johns Hopkins University
Interventions being studied
Drug: Subcutaneous Heparin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP
  • Patients who would have otherwise been eligible to receive routine post-RP care
Reasons someone may not be able to joinExclusion criteria
  • Active treatment for VTE
  • Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE)
  • Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)
  • Epidural analgesia
  • Spinal anesthesia
  • Participation in a different trial that increases a patient's risk of VTE

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Johns Hopkins HospitalBaltimore, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 5, 2020. Always confirm current availability with the study team.

View original record ↗